Vnitr Lek 2021, 67(5):291-295 | DOI: 10.36290/vnl.2021.076

Osteoporosis in diabetes mellitus patients

Peter Jackuliak, Magdaléna Kovářová, Martin Kužma, Juraj Payer
V. interná klinika Lekárskej fakulty UK a UN Bratislava

Diabetes mellitus (DM) is currently a pandemic problem, and the number of diabetic patients is constantly increasing. There are known and established diabetic complication but it is also comorbidities associated with DM cannot be forgotten. One of these is osteoporosis and osteoporotic fractures. In diabetic patients, the fractures are usually 2 to 6 times higher. In management of diabetes we should screen also the risk of osteoporosis and fractures. From a diabetic point of view, optimum glycaemic control should be achieved, however, we should take into account the effect of antidiabetic agents on bone. In this summary data on the diagnosis and treatment of osteoporosis in patients with DM as well as on the effect of antidiabetic agents on bone are presented.

Keywords: diabetes mellitus, osteoporosis, diagnosis, treatment.

Published: August 25, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jackuliak P, Kovářová M, Kužma M, Payer J. Osteoporosis in diabetes mellitus patients. Vnitr Lek. 2021;67(5):291-295. doi: 10.36290/vnl.2021.076.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Costantini S, Conte C. Bone health in diabetes and prediabetes. World J Diabetes, 2019. 10(8): p. 421-445. Go to original source... Go to PubMed...
    2. Shah VN, Shah CS, Snell-Bergeon JK. Type 1 diabetes and risk of fracture: meta-analysis and review of the literature. Diabetic medicine: a journal of the British Diabetic Association, 2015; 32(9): p. 1134-1142. Go to original source... Go to PubMed...
    3. Fan Y et al. Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int, 2016; 27(1): p. 219-228. Go to original source... Go to PubMed...
    4. Lipscombe LL et al. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care, 2007; 30(4): p. 835-841. Go to original source... Go to PubMed...
    5. Dhaliwal R et al. Determinants of fracture in adults with type 1 diabetes in the USA: Results from the T1D Exchange Clinic Registry. J Diabetes Complications, 2018; 32(11): p. 1006-1011. Go to original source... Go to PubMed...
    6. Moayeri A et al. Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther Clin Risk Manag, 2017; 13: p. 455-468. Go to original source... Go to PubMed...
    7. Wang H et al. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ Open, 2019; 9(1): p. e024067. Go to original source... Go to PubMed...
    8. Maurer MS, Burcham J, Cheng H. Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility. J Gerontol A Biol Sci Med Sci, 2005; 60(9): p. 1157-1162. Go to original source... Go to PubMed...
    9. Patel S et al. Risk factors for fractures and falls in older women with type 2 diabetes mellitus. Calcif Tissue Int, 2008; 82(2): p. 87-91. Go to original source... Go to PubMed...
    10. Picke A et al. Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. Endocrine connections, 2019; 8(3): p. R55-R70. Go to original source... Go to PubMed...
    11. Ferrari SL et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporosis International, 2018; 29(12): p. 2585-2596. Go to original source... Go to PubMed...
    12. Leslie WD et al. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab, 2013; 98(2): p. 602-609. Go to original source... Go to PubMed...
    13. Ebrahimpur M et al. Effect of diabetes on BMD and TBS values as determinants of bone health in the elderly: Bushehr Elderly Health program. Journal of Diabetes & Metabolic Disorders, 2019; 18(1): p. 99-106. Go to original source... Go to PubMed...
    14. Jackuliak P et al. Good long-term glycemic compensation is associated with better trabecular bone score in postmenopausal women with type 2 diabetes. Physiol Res, 2019; 68(Suppl 2): p. S149-s156. Go to original source... Go to PubMed...
    15. Schwartz AV et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. Jama, 2011; 305(21): p. 2184-2192. Go to original source... Go to PubMed...
    16. Leslie WD et al. Type 2 diabetes and bone. J Bone Miner Res, 2012; 27(11): p. 2231-2237. Go to original source... Go to PubMed...
    17. Giangregorio LM et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res, 2012; 27(2): p. 301-308. Go to original source... Go to PubMed...
    18. Keegan TH et al. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care, 2004; 27(7): p. 1547-1553. Go to original source... Go to PubMed...
    19. Cummings SR et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama, 1998; 280(24): p. 2077-2082. Go to original source... Go to PubMed...
    20. Dagdelen S et al. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Advances in Therapy, 2007; 24(6): p. 1314-1320. Go to original source... Go to PubMed...
    21. Inoue D et al. Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan. Calcified Tissue International, 2016; 98(2): p. 114-122. Go to original source... Go to PubMed...
    22. Johnell O et al. Associations Between Baseline Risk Factors and Vertebral Fracture Risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone and Mineral Research, 2004; 19(5): p. 764-772. Go to original source... Go to PubMed...
    23. Schwartz AV et al. Teriparatide in patients with osteoporosis and type 2 diabetes. Bone, 2016; 91: p. 152-158. Go to original source... Go to PubMed...
    24. Langdahl BL et al. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone, 2018; 116: p. 58-66. Go to original source... Go to PubMed...
    25. Zebaze R et al. Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis. J Bone Miner Res, 2016; 31(10): p. 1827-1834. Go to original source... Go to PubMed...
    26. Hayakawa N, Suzuki A. Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture. Clin Calcium, 2012; 22(9): p. 1383-1390. Go to PubMed...
    27. Jackuliak P et al. Effect of antidiabetic treatment on bone. Physiol Res, 2019; 68(Suppl 2): p. S107-s120. Go to original source... Go to PubMed...
    28. Paul T, Thomas N. Impact of oral antidiabetic agents on bone metabolism. Indian Journal of Medical Research, 2015; 141(4): p. 385-388. Go to original source... Go to PubMed...
    29. McCarthy AD, Cortizo AM, Sedlinsky C. Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy. World Journal of Diabetes, 2016; 7(6): p. 122-133. Go to original source... Go to PubMed...
    30. Gilbert MP, Pratley RE. The Impact of Diabetes and Diabetes Medications on Bone Health. Endocrine Reviews, 2015; 36(2): p. 194-213. Go to original source... Go to PubMed...
    31. Vestergaard P et al. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia, 2005; 48(7): p. 1292-1299. Go to original source... Go to PubMed...
    32. Schwartz AV. Diabetes and Metabolism of Bone, in ENDO 2017: Meet-The-Professor Endocrine Case Management, J. Leahy and A. Danoff, Editors. 2017: Washington DC. p. 63-65.
    33. Palermo A et al. Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. Osteoporos Int, 2015; 26(8): p. 2073-2089. Go to original source... Go to PubMed...
    34. Lecka-Czernik B. Safety of Anti-Diabetic Therapies on Bone. Clinical Rev Bone Miner Metab., 2013; 11(1): p. 49-58. Go to original source... Go to PubMed...
    35. Molinuevo MS et al. Effect of metformin on bone marrow progenitor cell differentiation: In vivo and in vitro studies. Journal of Bone and Mineral Research, 2010; 25(2): p. 211-221. Go to original source... Go to PubMed...
    36. Sundararaghavan V et al. Diabetes and bone health: latest evidence and clinical implications. Therapeutic Advances in Musculoskeletal Disease, 2017; 9(3): p. 67-74. Go to original source... Go to PubMed...
    37. Melton LJ et al. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res, 2008; 23(8): p. 1334-1342. Go to original source... Go to PubMed...
    38. Russo GT et al. Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences. International Journal of Endocrinology, 2016; 2016: p. 1615735. Go to original source... Go to PubMed...
    39. Mehta S. Comparative Safety of Oral Antidiabetic Therapy on Risk of Fracture in Patients with Diabetes, in American Diabetes Association 2014 Scientific Sessions; 2014: p. 165-OR.
    40. Medscape Sulfonylureas May Up Fracture Risk in Diabetes, Along With TZDs. 2014.
    41. Mieczkowska A et al. Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J Biol Chem, 2012; 287(28): p. 23517-23526. Go to original source... Go to PubMed...
    42. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Canadian Medical Association Journal, 2009; 180(1): p. 32-39. Go to original source... Go to PubMed...
    43. Ceccarelli E et al. Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism. Frontiers in Endocrinology, 2013; 4(73): p. 1-12. Go to original source... Go to PubMed...
    44. Monami M et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care, 2011; 34(11): p. 2474-2476. Go to original source... Go to PubMed...
    45. Nauck MA et al. Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care, 2011; 34(9): p. 2015-2022. Go to original source... Go to PubMed...
    46. List JF et al. Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes. Diabetes Care, 2009; 32(4): p. 650-657. Go to original source... Go to PubMed...
    47. Ljunggren Ö et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes, Obesity and Metabolism, 2012; 14(11): p. 990-999. Go to original source... Go to PubMed...
    48. Kohan DE et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney International, 2014; 85(4): p. 962-971. Go to original source... Go to PubMed...
    49. Watts NB et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. The Journal of Clinical Endocrinology and Metabolism, 2016; 101(1): p. 157-166. Go to original source... Go to PubMed...
    50. Campos Pastor MM et al. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int, 2000; 11(5): p. 455-459. Go to original source... Go to PubMed...
    51. Fowlkes JL et al. Contributions of the Insulin/Insulin-Like Growth Factor-1 Axis to Diabetic Osteopathy. Journal of diabetes & metabolism, 2011; 1(3): p. S1-003. Go to original source... Go to PubMed...
    52. Zhukouskaya VV et al. Bone Health in Type 1 Diabetes: Where We Are Now and How We Should Proceed. Advances in Endocrinology, 2014; 2014: p. 12. Go to original source...
    53. Kanazawa I et al. Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol, 2009; 160(2): p. 265-273. Go to original source... Go to PubMed...
    54. Chandran M. Diabetes Drug Effects on the Skeleton. Calcified Tissue International, 2017; 100(2): p. 133-149. Go to original source... Go to PubMed...
    55. Ferrari S. Diabetes and Bone. Calcif Tissue Int, 2017; 100(2): p. 107-108. Go to original source... Go to PubMed...
    56. Quandt SA et al. Predictors of Falls in a Multiethnic Population of Older Rural Adults With Diabetes. The journals of gerontology. Series A, Biological sciences and medical sciences, 2006; 61(4): p. 394-398. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.